Growth Promotion Test of Culture Media: A Practical Guide
Contents
- What growth promotion testing checks
- Growth promotion, suitability and sterility are different
- Which media and batches should be assessed?
- A practical workflow
- What to record in the media log
- Common mistakes
- Fictional example
- Frequently asked questions
- Is growth promotion needed for every medium lot?
- Does a growth promotion pass prove that a product method is suitable?
- Can I use a different organism or incubation condition?
- What should happen when growth promotion fails?
- Related reading
- References
In short: A growth promotion test checks whether a culture medium can support the microorganisms needed for the intended test. It helps microbiology teams decide whether a prepared or purchased medium is suitable for use. Use the current applicable pharmacopoeial chapter and approved procedure for organisms, conditions and acceptance criteria; there is no single set of conditions for every medium.
What growth promotion testing checks
Culture media are part of the measurement system in a microbiology laboratory. If a medium cannot support the intended organism, the test may fail to recover contamination even when the sample contains it. Growth promotion testing challenges the medium with appropriate microorganisms and confirms that it performs as intended for its assigned use.
This check is different from confirming that a medium is sterile. A sterility check asks whether unintended organisms are present in the medium. Growth promotion asks whether the medium supports the intended growth response. A medium may pass one check and fail the other, so the approved specification may call for both. For selective or differential media, the procedure may also assess inhibitory or indicative properties. The exact combination depends on the test and the medium.
The USP–NF chapters most often relevant to routine pharmaceutical microbiology include <61> for microbial enumeration, <62> for tests for specified microorganisms and <71> for sterility tests. The FDA Office of Regulatory Affairs’ Pharmaceutical Microbiology Manual describes media growth promotion and related properties for media used with USP <60>, <61> and <62>, and refers to USP <71> for sterility-test media. That manual supports inspection work; the current applicable compendial text, product requirements and approved laboratory procedure determine the actual method.
In India, check the controlled edition of the Indian Pharmacopoeia that applies to the product and market. IPC identifies IP 2026 as the tenth edition, published to fulfil the requirements of the Drugs and Cosmetics Act, 1940 and the Rules under it. Do not assume a USP chapter number has a one-to-one IP equivalent: confirm the applicable IP chapter and any amendments before writing or changing a procedure.
Growth promotion, suitability and sterility are different
| Check | Question it answers | Where it fits |
|---|---|---|
| Growth promotion | Does this medium support the expected growth response for the intended test? | Media qualification and preparation controls |
| Indicative or inhibitory property | Does the medium show the expected reaction, or suppress organisms it is meant to inhibit? | Selective and differential media, when required by the method |
| Method suitability | Can the product be tested without preventing recovery of the challenge organism? | Product-specific method suitability; see USP <1227> |
| Sterility check | Is the medium or test preparation free from unintended microbial growth? | Media or test controls, where required by the applicable procedure |
USP <1227> explains that compendial microbial procedures still require suitability to demonstrate recovery in the presence of the product. This is why a medium that passes its growth promotion check does not, by itself, prove that a product method is suitable. Read the sterility testing guide and the guide to specified microorganism testing for related method concepts.
Which media and batches should be assessed?
Start with the approved use of each medium: enumeration, detection of specified organisms, sterility testing, environmental monitoring or another defined application. The applicable method determines which media are needed and which properties must be checked. Avoid copying a strain list or incubation condition from an unrelated procedure.
The FDA ORA Pharmaceutical Microbiology Manual, document ORA.007 Revision 02 (2020), describes testing each batch of ready-prepared medium and each batch prepared from dehydrated medium or ingredients for growth promotion and, where appropriate, indicative and inhibitory properties. For sterility-test media, it says to follow the current USP chapter <71>. Treat this as inspectional guidance, not as a substitute for the current USP, IP or Ph. Eur. text applicable to your laboratory. The manual itself instructs readers to check its quality-management system for the most current official copy.
For every media type, the controlled procedure should make the scope clear. It should identify the medium, intended test, applicable chapter or approved method, required challenge organisms, test conditions, controls, acceptance criteria and responsibilities. If a supplier provides a certificate, define how the laboratory reviews and relies on it. A certificate does not automatically replace in-house qualification when the controlled method or quality system requires testing.
A practical workflow
- Identify the medium and its intended use. Record the name, formulation or catalogue reference, manufacturer, lot number, expiry and receipt condition. Confirm that the medium is approved for the test and that its storage and handling history are acceptable.
- Check the governing method. Use the current chapter, relevant product monograph and approved procedure. Confirm which properties apply: growth promotion alone, or also indicative, inhibitory, sterility or other checks. The organism panel and conditions are method-specific.
- Prepare the challenge and controls exactly as specified. Use qualified cultures or commercial preparations permitted by the method. Follow the current instructions for strain source, passage history, inoculum preparation, media handling and incubation. Do not borrow a small inoculum value, incubation time or temperature from a different chapter.
- Test representative portions using the specified technique. The method may require plates, broth, a particular inoculation approach or a defined recovery comparison. Include the negative or reference controls required by the governing text. Identify each vessel so results can be traced to the media lot and challenge culture.
- Read and compare the result with the specified criteria. Assess whether the expected growth, recovery, colour or inhibition response occurred. Use only the current acceptance criteria in the controlled chapter or method. Do not replace a compendial limit with a laboratory preference without the required scientific justification and approvals.
- Make a documented disposition. Record pass, fail or invalid status and the authorised decision. If a required test fails or a control is invalid, keep the affected medium from use while the laboratory follows its deviation and investigation procedure. Do not repeat until a passing result appears without resolving the original result.
- Release for the defined use. Make the result available to analysts before they use the medium. Preserve its identity, storage condition and expiry status through use. If a medium is repurposed or a preparation process changes, assess whether the qualification still covers that use.
What to record in the media log
The log should let another reviewer reconstruct what was tested and why the lot was accepted. Adapt this blank template to the laboratory’s controlled procedure; its fields are a practical example, not a pharmacopoeial form.
| Field | Entry |
|---|---|
| Medium name and intended method | |
| Supplier, catalogue or formulation reference | |
| Media lot, receipt date and expiry | |
| Preparation details and sterilisation record, if applicable | |
| Applicable chapter / procedure and version | |
| Challenge organism source and culture identifier | |
| Test conditions and control identifiers | |
| Observations, counts or other raw results | |
| Acceptance criteria and result | |
| Analyst, reviewer and disposition date | |
| Deviation or investigation reference, if applicable |
For records associated with a product batch, retain batch documentation at least one year after expiry of the respective product batch; EU GMP Volume 4, Chapter 4 §4.11 also specifies five years after Qualified Person certification, whichever is longer, and 21 CFR 211.180(a) sets a one-year-after-expiry minimum for applicable US drug-product records. Apply any longer product-specific or local requirement.
Common mistakes
- Using the wrong chapter or medium: A medium suitable for one analysis may not be suitable for another. Link each medium to its intended test and current method.
- Copying challenge conditions between procedures: Organisms, inoculum preparation and incubation conditions differ by method. Use the current applicable text and approved procedure.
- Treating the supplier certificate as a universal waiver: A certificate can support supplier oversight, but whether it replaces a laboratory test depends on the applicable standard and approved quality system.
- Confusing growth promotion with product method suitability: The medium check does not show that antimicrobial product properties have been neutralised or that the product method can recover organisms.
- Accepting unexplained control failures: An invalid control cannot support a confident conclusion about the medium. Investigate it and document the disposition.
- Leaving local choices unlabeled: If the laboratory adds a check beyond the pharmacopoeial method, label it clearly. Example in-house criterion: requiring an independent reviewer to release each qualified media lot is a site control, not a pharmacopoeial requirement.
Fictional example
A QC laboratory receives ready-to-use agar for a non-sterile product enumeration method. The analyst checks the approved method, confirms that the shipment and lot details match the receipt record, and performs the growth promotion work using the applicable chapter’s specified organisms, conditions and controls. The expected response is not obtained for one challenge. The analyst records the raw observation, keeps the affected lot from use and opens the site investigation. The laboratory reviews the result, culture and preparation records, incubator data and supplier information before deciding whether to reject the lot or repeat a justified, invalid test. No product result is accepted on the assumption that the agar was suitable.
Frequently asked questions
Is growth promotion needed for every medium lot?
Follow the current applicable chapter and the approved procedure. FDA’s ORA.007 Revision 02 manual describes testing each batch of prepared or ready-prepared media in the contexts it covers, but it is inspectional guidance. The controlling requirement for a specific test must be confirmed in the applicable pharmacopoeial text and quality system.
Does a growth promotion pass prove that a product method is suitable?
No. Growth promotion checks the medium. Method suitability checks whether the product or sample interferes with recovery under the test conditions. USP <1227> describes this distinction for compendial microbial recovery procedures.
Can I use a different organism or incubation condition?
Only where permitted and justified under the governing method and approved procedure. Do not change challenge organisms, incubation conditions or acceptance criteria by informal practice.
What should happen when growth promotion fails?
Do not release the affected medium for the intended use. Record the result, follow the site investigation procedure, assess any use that already occurred and document the authorised disposition. The investigation should address the control system and the validity of affected test results.
Related reading
- SOP for microbial culture management
- Preparation of anaerobic culture suspension
- Sterility testing in pharmaceutical products
- Specified microorganism testing
References
- United States Pharmacopeia, USP–NF General Chapter <61>, Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests (official USP preview identifies the chapter text as 2024): https://doi.org/10.31003/USPNF_M98800_02_01
- United States Pharmacopeia, USP–NF General Chapter <62>, Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms (2017 chapter text): https://doi.org/10.31003/USPNF_M98802_01_01
- United States Pharmacopeia, USP–NF General Chapter <71>, Sterility Tests (2017 chapter text): https://doi.org/10.31003/USPNF_M98810_01_01
- United States Pharmacopeia, USP–NF General Chapter <1227>, Validation of Microbial Recovery from Pharmacopeial Articles (2019): https://doi.org/10.31003/USPNF_M99947_03_01
- U.S. Food and Drug Administration, Office of Regulatory Affairs, Pharmaceutical Microbiology Manual, ORA.007 Revision 02 (25 August 2020): https://www.fda.gov/media/88801/download
- Electronic Code of Federal Regulations, 21 CFR 211.160 and 211.180(a), current text checked 6 November 2026: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/section-211.160 and https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/section-211.180
- European Commission, EudraLex Volume 4, Chapter 4: Documentation (revision 1, effective 30 June 2011): https://health.ec.europa.eu/document/download/104b3eb8-81a7-4858-9419-cb06562adb66_en?filename=chapter4_01-2011_en.pdf
- Indian Pharmacopoeia Commission, Introduction Pages IP 2026, tenth edition: https://www.ipc.gov.in/images/ARnD/Introduction-Pages-IP-2026.pdf
Related articles
Bacterial Endotoxins Test: Methods and Workflow
Understand bacterial endotoxin test methods, product suitability, controls and result review, with a practical workflow for pharma QC microbiology teams.
CCS Gap Assessment Checklist for Pharma Sterile Sites
Use this EU GMP Annex 1 based CCS gap assessment checklist to map contamination controls, record evidence, assess gaps and plan actions for a sterile site.
Pharma Microbiology Interview Questions for Freshers
Pharma microbiology interview questions for freshers with model answers on sterility testing, media, MLT, endotoxin, environmental monitoring and aseptic practice.
SOP on Maintenance and Preparation of Anaerobic Culture Suspension
Example SOP for maintaining Clostridium sporogenes and preparing an anaerobic culture suspension that delivers 10 to 100 CFU per inoculum for microbial limit testing.